🚨 84.4% CLINICAL BENEFIT: IVERMECTIN + MEBENDAZOLE CANCER STUDY A new peer-reviewed observational study looked at Ivermectin + Mebendazole in 197 cancer patients, and the six-month numbers are getting attention. Of the 197 patients, 122 completed the full six-month follow-up.